Tumor Infiltrating Lymphocytes (Nantes University Hospital)

N/A

Report date: 2022/02/22 17:59:37

Base Information

Drug NameTumor Infiltrating Lymphocytes (Nantes University Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionLymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNantes University Hospital

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNantes University Hospital

Active IndicationsN/A

Inactive IndicationsMelanoma

Other Information

ATC CodeN/A